The DOI matches its Crossref record.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
Open accessAbstract
Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous DAA‐containing regimens, particularly those with nonstructural protein 5A inhibitors, are limited and remain an area of unmet medical need. This phase 2, open‐label study (MAGELLAN‐1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) ± ribavirin (RBV) in HCV genotype 1–infected patients with prior virologic failure to HCV DAA‐containing therapy. A total of 50 patients without cirrhosis were randomized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 mg PIB with 800 mg once‐daily RBV (arm B), or 300 mg GLE + 120 mg PIB without RBV (arm C). By intent‐to‐treat analysis, sustained virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% confidence interval 61‐100), 95% (21/22, 95% confidence interval 78‐99), and 86% (19/22, 95% confidence interval 67‐95) of patients in arms A, B, and C, respectively. Virologic failure occurred in no patients in arm A and in 1 patient each in arms B and C (two patients were lost to follow‐up in arm C). The majority of adverse events were mild in severity; no serious adverse events related to study drug and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed. Conclusion : The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA‐containing therapy; RBV coadministration did not improve efficacy. (H epatology 2017;66:389–397).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Self-citationLevitsky, J., Formica, R. N., Bloom, R. D., Charlton, M., Curry, M., Friedewald, J., Friedman, J., Goldberg, D., Hall, S., Ison, M., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14381 · Cited by 327
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel, Heald, J., Demisashi, G., Durzy, E., Davis-Owino, A., & Tynes, S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad319 · Cited by 296
Glecaprevir/Pibrentasvir: First Global Approval
Lamb, Y. N. (2017) · Drugs · doi:10.1007/s40265-017-0817-y · Cited by 93
Metadata
- Authors
- Poordad, F., Felizarta, F., Asatryan, A., Sulkowski, M. S., Reindollar, R. W., Landis, C. S., Gordon, S. C., Flamm, S. L., Fried, M. W., Bernstein, D. E., Lin, C., Liu, R., Lovell, S. S., Ng, T. I., Kort, J., & Mensa, F. J.
- Venue
- Hepatology
- Published
- 2017-04-10
- Volume
- 66
- Issue
- 2
- Pages
- 389-397
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2667085915
- Cited by
- 198
- References
- 0
- FWCI
- 22.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment. https://app.cochat.ai/papers/10.1002/hep.29081
- The paper
- Poordad, F., Felizarta, F., Asatryan, A., Sulkowski, M. S., Reindollar, R. W., Landis, C. S., Gordon, S. C., Flamm, S. L., Fried, M. W., Bernstein, D. E., Lin, C., Liu, R., Lovell, S. S., Ng, T. I., Kort, J., & Mensa, F. J. (2017). Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment. Hepatology. https://doi.org/10.1002/hep.29081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.